News & Updates

In the preplanned overall survival (OS) interim analysis of the monarchE study, the combination of abemaciclib and endocrine therapy (ET) continued to provide benefit for individuals with HR+, HER2–, node-positive, high-risk early breast cancer even after completion of therapy.

Anti-inflammatory dietary patterns, such as the Mediterranean diet, may improve the chances of conception among couples who struggle with infertility, according to a recent review.

In the updated analysis of the phase III EMERALD trial, the next-generation oral SERD* elacestrant continued to show favourable signals for the treatment of ER+/HER2– metastatic breast cancer (mBC).

Among patients with prediabetes or polycystic ovary syndrome (PCOS), the use of metformin appears to be associated with lower incidence of severe COVID-19, according to a study.

In the final overall survival (OS) analysis of the phase III PAOLA-1*/ENGOT-ov25 trial, the addition of olaparib to bevacizumab provided a survival benefit for women with newly diagnosed advanced ovarian cancer with HRD**-positive (HRD+) tumours.

Among women with a history of gestational diabetes mellitus (GDM), the conversion to prediabetes or type 2 diabetes mellitus (T2DM) appears to be high, a recent study has found.